Results 211 to 220 of about 21,216 (279)

SWITCH DE RALTEGRAVIR PARA DOLUTEGRAVIR EM PACIENTES COM FALHA TERAPÊUTICA PRÉVIA – QUAL O IMPACTO NA SUPRESSÃO VIROLÓGICA?

, 2018
Melissa Soares Medeiros, José Edvar di Castro Júnior, Yandra Mirelle Nogueira, Antonio Erisval Linhares Ponte Filho, Leticia Sucupira Cristino, Juliana Sampaio Saraiva De Oliv, Larissa Costa Amorim, Priscyla Ferreira Araripe, Karina Vasconcelos Nor, Kilmer de Moraes Castelo Branco, Lucy Cavalcanti Ramos Vasconcel, Gustavo Igor Marques Rodrigu   +11 more
openalex   +1 more source

Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2--LTR Circles Over 12 Weeks. [PDF]

Open Forum Infect Dis
Reed JC, Hall L, McKhann A, Kwak G, Goecker EA, Coombs RW, Chen H, Roa J, Vecchio A, Daar ES, Hunt PW, Marra CM, Campbell TB, Ma Q, Swaminathan S, Macatangay BJC, Morse GD, Miller T, Rusin D, Ha B, Alston-Smith B, Paul R, Letendre SL, Spudich SS, Greninger AL.   +24 more
europepmc   +1 more source

Erratum for Dinh et al., "The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir". [PDF]

mBio
Dinh T, Tber Z, Rey JS, Mengshetti S, Annamalai AS, Haney R, Briganti L, Amblard F, Fuchs JR, Cherepanov P, Kim K, Schinazi RF, Perilla JR, Kim B, Kvaratskhelia M.   +14 more
europepmc   +1 more source

HIV-1 and SIV Infection are associated with early loss of lung interstitial CD4+ T cells and dissemination of pulmonary tuberculosis [PDF]

, 2019
et al,, Khader, Shabaana A
core   +1 more source

Brief communication: characteristics of primary drug resistance in newly diagnosed HIV-infected individuals in Ganzhou, China. [PDF]

AIDS Res Ther
Huang DD, Liu JJ, Chen YT, Yang RR, Su JZ, Gao Q, Chen X.   +6 more
europepmc   +1 more source

Changes in Bone Mineral Density through 96 Weeks in Antiretroviral-Naïve HIV-1 Infected Patients Receiving Abacavir/Lamivudine and Raltegravir in the SHIELD Trial

, 2014
Linda Battalora, Amy Thomas, Brian Wine, Belinda Ha, Benjamin Young   +4 more
openalex   +2 more sources

Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial treatment for people living with HIV. [PDF]

Clin Trials
Zheng Y, Currier JS, Hughes MD.
europepmc   +1 more source

Pharmacokinetic Adaptations in Pregnancy: Implications for Optimizing Antiretroviral Therapy in HIV-Positive Women. [PDF]

Pharmaceutics
Briceño-Patiño N, Prieto MC, Manrique P, Calderon-Ospina CA, Gómez L.   +4 more
europepmc   +1 more source

Combining spironolactone to antiretroviral therapy accelerates HIV decay in humanized mice. [PDF]

Emerg Microbes Infect
Ling L, Mori LP, Soper A, Yao W, McAuley AT, Leda AR, Spagnuolo RA, Begum N, Kovarova M, Wahl A, Cameron MD, Valente ST, Garcia JV.   +12 more
europepmc   +1 more source

Preswitch Regimens Associated With Weight Gain Among Persons With HIV who Switch to Integrase Inhibitor-Containing Regimens. [PDF]

Open Forum Infect Dis
Cutshaw MK, Harding M, Davenport CA, Okeke NL.   +3 more
europepmc   +1 more source